Acute myeloid leukemia management and research in 2025
CA: A Cancer Journal for Clinicians · 2025-01 · 75 (1) · 46-67
DOI: 10.3322/caac.21873 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift CA: A Cancer Journal for Clinicians, online erschienen am 10.12.2024. Verfasst von Hagop M Kantarjian und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Antineoplastic Agents. Die Arbeit wurde bisher 121-mal zitiert (Crossref) und nennt 211 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
The first 5 decades of research in acute myeloid leukemia (AML) were dominated by the cytarabine plus anthracyclines backbone, with advances in strategies including allogeneic hematopoietic stem cell transplantation, high‐dose cytarabine, supportive care measures, and targeted therapies for the subset of patients with acute promyelocytic leukemia. Since 2017, a turning point in AML research, 12 agents have received regulatory approval for AML in the United States: venetoclax (BCL2 inhibitor); gemtuzumab ozogamicin (CD33 antibody–drug conjugate); midostaurin, gilteritinib, and quizartinib (fms‐like tyrosine kinase 3 inhibitors); ivosidenib, olutasidenib, and enasidenib (isocitrate dehydrogenase 1 and 2 inhibitors); oral azacitidine (a partially absorbable formulation); CPX351 (liposomal encapsulation of cytarabine:daunorubicin at a molar ratio of 5:1); glasdegib (hedgehog inhibitor); and recently revumenib (menin inhibitor; approved November 2024). Oral decitabine‐cedazuridine, which is approved as a bioequivalent alternative to parenteral hypomethylating agents in myelodysplastic syndrome, can be used for the same purpose in AML. Menin inhibitors, CD123 antibody–drug conjugates, and other antibodies targeting CD123, CD33, and other surface markers are showing promising results. Herein, the authors review the frontline and later line therapies in AML and discuss important research directions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Division of Hematology/Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA.
- Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Karmanos Cancer Center, Wayne State University School of Medicine, Detroit, Michigan, USA.
- START Center for Cancer Care, San Antonio, Texas, USA.
ORCID-Profile: Hagop M Kantarjian, Courtney D DiNardo, Naval G Daver, Farhad Ravandi
Förderung
- NCI NIH HHS
Zitieren
APA
Kantarjian, H. M., DiNardo, C. D., Kadia, T. M., Daver, N. G., Altman, J. K., Stein, E. M., Jabbour, E., Schiffer, C. A., Lang, A., & Ravandi, F. (2025). Acute myeloid leukemia management and research in 2025. CA: A Cancer Journal for Clinicians, 75(1), 46-67. https://doi.org/10.3322/caac.21873
Vancouver
Kantarjian HM, DiNardo CD, Kadia TM, Daver NG, Altman JK, Stein EM, et al. Acute myeloid leukemia management and research in 2025. CA: A Cancer Journal for Clinicians. 2025;75(1):46-67. doi:10.3322/caac.21873
BibTeX
@article{Kantarjian2025,
author = {Kantarjian, Hagop M and DiNardo, Courtney D and Kadia, Tapan M and Daver, Naval G and Altman, Jessica K and Stein, Eytan M and Jabbour, Elias and Schiffer, Charles A and Lang, Amy and Ravandi, Farhad},
title = {Acute myeloid leukemia management and research in 2025},
journal = {CA: A Cancer Journal for Clinicians},
year = {2025},
volume = {75},
number = {1},
pages = {46--67},
doi = {10.3322/caac.21873}
}
EUVIMED